| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Earnings call: Cardiff Oncology reports on CRDF-004 trial progress | 9 | Investing.com | ||
| Do | Cardiff Oncology Inc reports results for the quarter ended in March - Earnings Summary | 3 | Reuters | ||
| Do | Cardiff Oncology, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| Do | Cardiff Oncology, Inc. - 10-Q, Quarterly Report | 5 | SEC Filings | ||
| 25.04. | Cardiff Oncology, Inc.: Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update | 9 | GlobeNewswire (USA) | ||
| 08.04. | Cardiff Oncology, Inc.: Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study | 127 | GlobeNewswire (Europe) | RAS-mutated mCRC - In RAS-mutated mCRC, novel preclinical finding demonstrates onvansertib inhibits the tumor's ability to adapt to hypoxia resulting in a significant decrease in both tumor vascularization... ► Artikel lesen | |
| 08.04. | Cardiff Oncology, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| 27.03. | Cardiff Oncology, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 10 | SEC Filings | ||
| 06.03. | Cardiff Oncology, Inc.: Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024 | 215 | GlobeNewswire (Europe) | SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of... ► Artikel lesen | |
| 01.03. | Earnings call: Cardiff Oncology reports promising trial results, extends cash runway | 18 | Investing.com | ||
| 01.03. | Small Cap-Cardiff Oncology Outlines Data From Discontinued Colorectal Cancer Trial, Stock Soars | 12 | Benzinga.com | ||
| 01.03. | Cardiff Oncology, DermTech, Precision Biosciences among healthcare movers | 8 | Seeking Alpha | ||
| 01.03. | Cardiff Oncology Inc reports results for the quarter ended in December - Earnings Summary | 21 | Reuters | ||
| 29.02. | Cardiff Oncology, Inc.: Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC | 419 | GlobeNewswire (Europe) | - New clinical data from second-line randomized ONSEMBLE trial provides further evidence of the efficacy of onvansertib in combination with FOLFIRI/bev in bev naïve RAS-mutated mCRC patients - - Company... ► Artikel lesen | |
| 29.02. | Cardiff Oncology, Inc.: Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update | 181 | GlobeNewswire (Europe) | - First patient dosed in Phase 2 first-line trial in patients with RAS-mutated mCRC for new lead program with the support of FDA and clinical execution from Pfizer Ignite - - Interim topline data... ► Artikel lesen | |
| 29.02. | Cardiff Oncology, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 29.02. | Cardiff Oncology, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
| 28.02. | Cardiff Oncology Earnings Preview | 5 | Benzinga.com | ||
| 17.01. | Cardiff Oncology, Inc.: Cardiff Oncology Announces Publication of Data from Phase 1b study in second-line KRAS-mutated mCRC in Clinical Cancer Research | 251 | PR Newswire | - Findings from the Phase 1b portion of company's Phase 1b /2 study in second-line KRAS-mutated mCRC highlight the safety and promising efficacy of onvansertib in combination with standard-of-care... ► Artikel lesen | |
| 08.01. | Cardiff Oncology, Inc. - 8-K, Current Report | 4 | SEC Filings |
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| EVOTEC | 2.806 |
| NEL | 1.628 |
| APPLE | 1.509 |
| BAYER | 1.467 |
| BYD | 1.467 |
| SUPER MICRO COMPUTER | 1.351 |
| DEUTSCHE BANK | 1.232 |
| TUI | 1.207 |
| NVIDIA | 1.200 |
| PLUG POWER | 1.060 |
| TESLA | 1.009 |
| DAIMLER TRUCK | 934 |
| MERCEDES-BENZ | 908 |
| RHEINMETALL | 886 |
| RWE | 885 |
| AURUBIS | 800 |
| RENK GROUP | 779 |
| DEUTSCHE LUFTHANSA | 773 |
| COMMERZBANK | 755 |
| VOLKSWAGEN | 752 |
| AMAZON | 742 |
| SIEMENS ENERGY | 688 |
| AIXTRON SE | 664 |
| SIXT SE VZ | 644 |
| ALLIANZ | 609 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
